Maxigesic(R) IV launches in Germany and Austria

8th July 2021 Maxigesic(R) IV launches in Germany and Austria Commercialisation of Maxigesic IV in Europe is progressing well with launches and further registrations. AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces its licensee Ever Pharma has launched the intravenous form of its patented pain relief medicine Maxigesic in Germany, the largest European pharmaceutical market for post-operative pain relief*, and Austria. Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion and has European patents extending to 2035. AFT Pharmaceuticals has made good progress commercialising the medicine around the world. It is now licensed in 100 countries across the globe and it has been registered in 24 other countries. Following the launch in German and Austria it is now for sale in five countries including Australia, New Zealand, the United Arab Emirates as well as the two new European states. AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said "the launch of Maxigesic IV in Germany, the largest pharmaceutical market in the EU, and Austria is a significant milestone in the commercialisation of the medicine. Annually, over 5.2 million surgical procedures are performed in Germany, and the market for postoperative pain in Germany is expected to grow to 166.5 million USD by 2028 at a CAGR of 11.58% from 2017-2028*. " "The launch represents the start of the roll-out across Europe, where we see significant potential for the medicine. Indeed, while sales of the medicine in the current financial year are not expected to be material, we see a rapid ramp up as we launch the medicine across multiple markets including larger markets such as the US. "Presently we are completing Maxigesic IV registrations in Denmark, Finland, Iceland, Ireland, Greece, Norway and Sweden. We will then be working to launch in all these territories during the current financial year," said Dr Atkinson. "We also continue to strengthen our base in Europe, in November last year we created AFT Pharmaceuticals Europe and appointed a Director, Eddie Townsley. Meanwhile, one of our business development staff is moving to London in late August to further support and drive our European sales." Stijn Van Rompay, Chief Executive Officer of AFT's co-development partner Hyloris, commented: "We are pleased that AFT and its partner Ever Pharma have now launched Maxigesic IV in Germany and Austria. "We are convinced that Ever Pharma is the ideal partner to make this valuable new non-addictive pain treatment available to patients in Germany and Austria given their strong footprint in key European markets, and their expertise with complex injectables in multiple therapeutic areas, including anaesthesia. "We look forward to continuing to update the market as we, and our partner AFT, make further progress in the regulatory activities, launches and further roll-out of Maxigesic IV across the globe." For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO * Postoperative Pain Market Insights, Epidemiology and Market Forecast - 2028. Delveinsight. For more information: Investors Media Dr Hartley Atkinson Richard Inder Managing Director The Project AFT Pharmaceuticals Tel: +64 21 645 643 Tel: +64 9488 0232 About Maxigesic(R) IV Maxigesic IV has been developed under the development collaboration agreement signed in 2012 between AFT Pharmaceuticals and Hyloris. Maxigesic IV is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion for use post-operatively. Results from a randomised, double-blind, placebo-controlled Phase 3 trial in 276 patients following bunion surgery demonstrated that Maxigesic IV was well-tolerated and had a faster onset of action and offered higher pain relief compared to ibuprofen IV or paracetamol IV alone in the same doses. Moreover, the superior analgesic effect of Maxigesic IV was supported by a range of secondary endpoints, including reduced opioid consumption compared to the paracetamol IV and ibuprofen IV treatment groups (P<0.005). In addition, the safety and tolerability of repeated doses of Maxigesic IV over an extended period was assessed in an open-label, multi-centre, single arm study in 232 patients undergoing orthopaedic or plastic surgery. This extension study demonstrated that Maxigesic IV, administered 6-hourly as a 15-minute infusion between 48 hours to 5 days was safe and well-tolerated, and was perceived positively by study participants, supporting a favourable risk benefit profile. Under the terms of the collaboration agreement with AFT, Hyloris is eligible to a minority share of Maxigesic IV related income generated by AFT, excluding income generated in Australia and New Zealand. About AFT Pharmaceuticals AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com. End CA:00375283 For:AFT Type:GENERAL Time:2021-07-08 08:30:34